IRIS
RESTEGHINI, CARLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 2.257
NA - Nord America 1.667
SA - Sud America 430
EU - Europa 274
AF - Africa 42
OC - Oceania 1
Totale 4.671
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.576
SG - Singapore 1.398
CN - Cina 430
BR - Brasile 365
VN - Vietnam 197
IT - Italia 82
HK - Hong Kong 65
CA - Canada 51
GB - Regno Unito 48
IN - India 43
DE - Germania 42
AR - Argentina 30
BD - Bangladesh 27
MX - Messico 25
FR - Francia 24
ZA - Sudafrica 16
PL - Polonia 15
IQ - Iraq 14
EC - Ecuador 13
ID - Indonesia 13
PK - Pakistan 11
RU - Federazione Russa 11
ES - Italia 10
JP - Giappone 10
VE - Venezuela 9
SE - Svezia 8
TR - Turchia 8
CO - Colombia 6
KE - Kenya 6
MY - Malesia 6
UZ - Uzbekistan 6
IE - Irlanda 5
MA - Marocco 5
NL - Olanda 5
NP - Nepal 5
SA - Arabia Saudita 5
UA - Ucraina 5
AE - Emirati Arabi Uniti 3
DZ - Algeria 3
ET - Etiopia 3
JO - Giordania 3
KZ - Kazakistan 3
OM - Oman 3
PY - Paraguay 3
RO - Romania 3
AL - Albania 2
AT - Austria 2
BB - Barbados 2
CR - Costa Rica 2
EG - Egitto 2
HR - Croazia 2
LT - Lituania 2
NI - Nicaragua 2
PA - Panama 2
PH - Filippine 2
TN - Tunisia 2
AM - Armenia 1
AU - Australia 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BE - Belgio 1
BG - Bulgaria 1
BH - Bahrain 1
BM - Bermuda 1
BO - Bolivia 1
BW - Botswana 1
CH - Svizzera 1
CI - Costa d'Avorio 1
CL - Cile 1
CZ - Repubblica Ceca 1
DO - Repubblica Dominicana 1
FI - Finlandia 1
GA - Gabon 1
GT - Guatemala 1
HN - Honduras 1
IL - Israele 1
JM - Giamaica 1
KR - Corea 1
NG - Nigeria 1
PE - Perù 1
RS - Serbia 1
SI - Slovenia 1
SR - Suriname 1
TT - Trinidad e Tobago 1
UG - Uganda 1
VI - Stati Uniti Isole Vergini 1
Totale 4.671
Salva come PNG Salva come JPEG
Città #
Singapore 585
San Jose 372
Ashburn 332
The Dalles 200
Beijing 148
Shanghai 147
Dallas 93
Ho Chi Minh City 67
Hong Kong 58
Hanoi 41
Santa Clara 41
Los Angeles 40
New York 37
Buffalo 29
São Paulo 28
Seattle 26
Assago 20
Boardman 19
Montreal 19
Brooklyn 18
Naples 15
Rio de Janeiro 14
Warsaw 13
Mexico City 12
Düsseldorf 11
Frankfurt am Main 11
Haiphong 10
Orem 10
Tokyo 10
Brasília 9
Chennai 9
Chicago 9
Johannesburg 9
Milan 8
Paris 8
Phoenix 8
Atlanta 7
Da Nang 7
London 7
Munich 7
Stockholm 7
Toronto 7
Belo Horizonte 6
Nairobi 6
Quito 6
San Francisco 6
Tashkent 6
Boston 5
Curitiba 5
Manchester 5
Monza 5
Porto Alegre 5
Portsmouth 5
Ribeirão Preto 5
Baghdad 4
Biên Hòa 4
Buenos Aires 4
Bắc Ninh 4
Campinas 4
Caruaru 4
Charlotte 4
Cotia 4
Denver 4
Duque de Caxias 4
Guayaquil 4
Mumbai 4
Poplar 4
Roubaix 4
Salvador 4
Secaucus 4
Addis Ababa 3
Amman 3
Ankara 3
Bengaluru 3
Bologna 3
Camaçari 3
Can Tho 3
Cape Town 3
Cincinnati 3
City of London 3
Conselheiro Lafaiete 3
Dublin 3
Edmonton 3
Faisalabad 3
Genoa 3
Goiânia 3
Houston 3
Istanbul 3
Jakarta 3
Joinville 3
Lahore 3
Louisville 3
Natal 3
Nha Trang 3
São José do Rio Preto 3
Tatuí 3
Thái Bình 3
Thái Nguyên 3
Trieste 3
Uberlândia 3
Totale 2.747
Salva come PNG Salva come JPEG
Nome #
Precision medicine in Salivary Gland Carcinoma: Insights from breast and prostate cancer 95
Management of loco-regionally advanced squamous laryngeal cancer in elderly patients 92
Treatment-related mortality in head and neck cancer patients receiving chemotherapy and radiation: results of a meta-analysis of published trials 79
A pilot study of a smartphone-based monitoring intervention on head and neck cancer patients undergoing concurrent chemo-radiotherapy 75
The Interplay between Age and Viral Status in EBV-Related Nasopharyngeal and HPV-Related Oropharyngeal Carcinoma Patients 70
A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: Translational analyses and clinical impact 69
Abiraterone Acetate in Patients With Castration-Resistant, Androgen Receptor-Expressing Salivary Gland Cancer: A Phase II Trial 61
Lenvatinib in Relapsed/Metastatic Adenoid Cystic Carcinoma: Real-World Data From 17 Italian Centers 56
Anticipation of the Impact of Human Papillomavirus on Clinical Decision Making for the Head and Neck Cancer Patient 54
Patients with adenoid cystic carcinomas of the salivary glands treated with lenvatinib: Activity and quality of life 54
The association of cemiplimab plus sonidegib for synchronous cutaneous squamous cell carcinoma and basal cell carcinoma of the head and neck: Two case reports 54
A multicenter randomized trial for quality of life evaluation by non-invasive intelligent tools during post-curative treatment follow-up for head and neck cancer: Clinical study protocol 54
Big Data in Head and Neck Cancer 53
Immunotherapy followed by cetuximab in locally advanced/metastatic (LA/M) cutaneous squamous cell carcinomas (cSCC): The I-TACKLE trial 52
Nasopharyngeal cancer in non-endemic areas: Impact of treatment intensity within a large retrospective multicentre cohort 52
Baseline neutrophil-to-lymphocyte ratio is associated with outcome in recurrent/metastatic head and neck squamous cell cancer patients treated with platinum and cetuximab in first line setting 51
Salivary Cytokine Levels and Oral Mucositis in Head and Neck Cancer Patients Treated With Chemotherapy and Radiation Therapy 51
Does a multidisciplinary team approach in a tertiary referral centre impact on the initial management of head and neck cancer? 51
A retrospective cohort study of PD-L1 expression in recurrent and/or metastatic squamous cell carcinoma of the head and neck (SUPREME-HN). 51
Bone metastases from head and neck malignancies: Prognostic factors and skeletal-related events 50
Fentanyl pectin nasal spray as treatment for incident predictable breakthrough pain (BTP) in oral mucositis induced by chemoradiotherapy in head and neck cancer 50
Health care-associated infections (HAIs) in head and neck carcinoma (HNC) patients treated with chemotherapy (CT) and/or radiotherapy (RT) 50
Age related toxicity and outcome in oropharyngeal and nasoparyngeal cancer patients 49
Temporal course and predictive factors of analgesic opioid requirement for chemoradiation-induced oral mucositis in oropharyngeal cancer 49
BRAF V600E-mutated anaplastic thyroid carcinoma (ATC) and treatment with BRAF-inhibitors: Real-world data from a single-institution, still far from the cure 49
Circulating pre-treatment Epstein-Barr virus DNA as prognostic factor in locally-advanced nasopharyngeal cancer in a non-endemic area 49
Prognostic and predictive value of EGFR in head and neck squamous cell carcinoma 48
Sinonasal malignancy: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up 48
RANK expression in EBV positive nasopharyngeal carcinoma metastasis: A ready-to-treat target? 47
Activity of platinum and cetuximab in cutaneous squamous cell cancer not amenable to curative treatment 47
The Evolving Role of Systemic Therapy in the Primary Treatment of Sinonasal Cancer 47
BD4QoL: A multicenter randomized trial for monitoring quality of life (QoL) by intelligent tools in head and neck cancer (HNC) survivors after curative treatment 47
Management of tyrosine kinase inhibitors (TKI) side effects in differentiated and medullary thyroid cancer patients 46
Surveillance of Patients with Head and Neck Cancer with an Intensive Clinical and Radiologic Follow-up 46
The SINTART 2 Study. A phase II non-randomised controlled trial of induction chemotherapy, photon-, proton- and carbon-ion-based radiotherapy integration in patients with locally advanced unresectable sinonasal tumours 46
Efficacy and safety of single-agent pan-human epidermal growth factor receptor (HER) inhibitor dacomitinib in locally advanced unresectable or metastatic skin squamous cell cancer 45
A multicentre retrospective analysis of recurrent/metastatic (RM) nasopharyngeal cancer (NPC) from non-endemic areas: Results in the pre-immunotherapy era 45
Prognostic nomogram in patients with metastatic adenoid cystic carcinoma of the salivary glands 45
Do not throw the baby out with the bathwater: SELECT a personalized, de-escalated lenvatinib schedule allows response in locally advanced DTC while controlling major drug-related bleeding 45
An added value to Multidisciplinary Team: does a Tutor help to manage head and neck cancer patients? 45
The SINTART 1 study. A phase II non-randomised controlled trial of induction chemotherapy, surgery, photon-, proton- and carbon ion-based radiotherapy integration in patients with locally advanced resectable sinonasal tumours 45
Circulating pretreatment Epstein Barr Virus DNA quantification as a prognostic factor in nasopharyngeal cancer patients in a non endemic area 44
Monitoring patients with head and neck cancer for flu-like symptoms during the COVID-19 pandemic 44
The SINTART 1 study: A phase II trial of induction chemotherapy (IC), surgery, photon-, proton-and carbon ion-based radiotherapy (RT) integration in locally advanced operable sinonasal epithelial tumors patients (pts) 44
RetroSpective cohort stUdy of PD-L1 expression in REcurrent and/or MEtastatic (R/M) squamous cell carcinoma of the head and neck (SUPREME-HN) 44
Transcriptomic and tumor microenvironment landscape of EBV related nasopharyngeal carcinoma in endemic and non-endemic areas 43
HER2 status in recurrent/metastatic androgen receptor overexpressing salivary gland carcinoma patients 43
RetroSpective cohort stUdy of PD-L1 expression in REcurrent and/or MEtastatic squamous cell carcinoma of the head and neck (SUPREME-HN) 43
Locally advanced epithelial sinonasal tumors: The impact of multimodal approach 43
Health care-associated infections in patients with head and neck cancer treated with chemotherapy and/or radiotherapy 43
A phase II trial of dacomitinib in locally advanced unresectable or metastatic skin squamous cell carcinoma 43
A phase II trial of induction chemotherapy (IC), photon-, proton- and carbon ion-based radiotherapy (RT) integration in locally advanced inoperable sinonasal epithelial tumors patients (pts) 42
Mining of self-organizing map gene-expression portraits reveals prognostic stratification of HPV-positive head and neck squamous cell carcinoma 42
Refining Tumor Treatment in Sinonasal Cancer Using Delta Radiomics of Multi-Parametric MRI after the First Cycle of Induction Chemotherapy 42
A retrospective multicenter Italian analysis of the effect of longer vismodegib intake in 68 basal cell carcinoma patients who achieved clinical complete remission 42
Low etiologic fraction for human papillomavirus in larynx squamous cell carcinoma 42
Genomics in non-adenoid cystic group of salivary gland cancers: one or more druggable entities? 41
Systemic therapy in metastatic salivary gland carcinomas: A pathology-driven paradigm? 41
Phase II trial with axitinib in recurrent and/or metastatic salivary gland cancers of the upper aerodigestive tract 41
Relevance of apparent diffusion coefficient features for a radiomics-based prediction of response to induction chemotherapy in sinonasal cancer 41
Outcome of recurrent and metastatic head and neck squamous cell cancer patients after first line platinum and cetuximab therapy 40
PD-L1 Expression in Unresectable Locally Advanced or Metastatic Skin Squamous Cell Carcinoma Treated with Anti-Epidermal Growth Factor Receptor Agents 40
Phase 2 study on axitinib in recurrent/metastatic salivary gland cancer of upper aerodigestive tract 39
SUPREME-HN: a retrospective biomarker study assessing the prognostic value of PD-L1 expression in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck 39
RANK expression in EBV associated nasopharyngeal cancer metastasis in non-endemic setting: a possible immunologic pathway to be targeted? 39
Efficacy and safety of single agent pan-HER inhibitor dacomitinib in locally advanced unresectable or metastatic skin squamous cell cancer (sSCC). 39
Treatment Options for Recurrent Anterior Skull Base Tumors 39
Immunotherapy followed by cetuximab in locally advanced/metastatic cutaneous squamous cell carcinomas: the I-TACKLE trial 39
Prognostic role of primary tumor, nodal neck, and retropharyngeal GTVs for unresectable sinonasal cancers treated with IMRT and chemotherapy 38
Transcriptomics and Epigenomics in head and neck cancer: available repositories and molecular signatures 38
Clinical prognostic factors in patients with recurrent or metastatic carcinoma of the head and neck treated with immune checkpoints therapies. 38
Could the extreme conformality achieved with proton therapy in paranasal sinuses cancers accidentally results in a high rate of leptomeningeal progression? 37
HEALTHCARE ASSOCIATED INFECTIONS IN HEAD AND NECK CARCINOMA PATIENTS TREATED WITH CHEMOTHERAPY AND/OR RADIOTHERAPY 37
Immunotherapy in nonendemic nasopharyngeal carcinoma: Real-world data from two nonendemic regions 37
Pre-treatment risk factors to predict early cisplatin-related nephrotoxicity in locally advanced head and neck cancer patients treated with chemoradiation: A single Institution experience 37
Mutational profile of epithelial, non-glandular sinonasal cancers into 2 prospective clinical trials 37
A single institution twenty-year experience of recurrent or metastatic epithelial non glandular sinonasal cancer 37
Phase II study on lenvatinib (LEN) in recurrent and/or metastatic (R/M) adenoid cystic carcinomas (ACC) of the salivary glands (SG) of the upper aereodigestive tract (NCT02860936) 36
Hedgehog Inhibitors Beyond Clinical Complete Response in Basal Cell Carcinoma: Should I Stop or Should I Go? 36
Druggable molecular targets in skin adnexal malignancies 36
Prolonged response using gefitinib followed by sirolimus for advanced cutaneous squamous cell carcinoma 36
Prognostic role of PIK3CA and TP53 in human papillomavirus–negative oropharyngeal cancers 35
Retrospective analysis of baseline clinical factors associated to CDDP-nephrotoxicity in locally advanced head and neck cancer (LAHNC) patients 35
Local therapies for liver metastases of rare head and neck cancers: A monoinstitutional case series 35
Multidisciplinary management of pregnancy-associated and early post-partum head and neck cancer patients 34
Survival differences between EU and Asia for head and neck cancer: Results of the RARECAREnet-Asia collaboration 34
Head and neck cancers survival in Europe, Taiwan, and Japan: results from RARECAREnet Asia based on a privacy-preserving federated infrastructure 34
Outcome of systemic treatments after first line platinum and cetuximab treatment in patients with recurrent/metastatic (RM) head and neck squamous cell cancer (HNSCC): A retrospective analysis 33
Retreatment with Vismodegib is active in progressive advanced Basal Cell Carcinoma: first report from a single-Institution experience 33
Treatment-associated mortality in head and neck cancer receiving chemotherapy and radiation: Meta-analysis of published trials 33
Nausea and vomiting during the first 3 intercycle periods in chemo-naive cancer patients receiving moderately/highly emetogenic therapy 33
Immunotherapy in head and neck squamous cell carcinoma and rare head and neck malignancies 33
Role of induction chemotherapy in the multimodal management of locally advanced epithelial sinonasal cancer 33
Role of induction chemotherapy in the multimodal management of locally advanced epithelial sinonasal cancer: a single center experience 33
Late toxicities burden in patients with radioiodine-refractory differentiated thyroid cancer treated with lenvatinib 32
Radiomics-based prediction of response to multikinase inhibitors in radioiodine-refractory differentiated thyroid cancer patients 32
Radiomics-based prediction of response to induction chemotherapy in sinonasal cancer 32
Tumor molecular landscape of Epstein-Barr virus (EBV) related nasopharyngeal carcinoma in EBV-endemic and non-endemic areas: Implications for improving treatment modalities 32
Hyperprogressive disease (HPD) in head and neck squamous cell carcinoma (HNSCC) patients treated with immune checkpoint inhibitors (ICI) 32
Site of metastatic disease influences adenoid cystic cancer (ACC) patients' outcome 31
Totale 4.443
Salva come PNG Salva come JPEG
Categoria #
all - tutte 27.379
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 27.379
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2023/2024372 0 0 0 0 0 0 0 57 52 45 90 128
2024/20251.164 44 5 4 7 7 113 53 67 211 287 182 184
2025/20263.254 515 191 166 227 156 230 941 130 160 211 185 142
Totale 4.790